Non-randomized, three-period, fixed-sequence, multiple-dose trial, open label study of drug- drug interaction between doravirine, elbasvir and grazoprevir
Latest Information Update: 27 Feb 2019
At a glance
- Drugs Doravirine (Primary) ; Elbasvir (Primary) ; Grazoprevir (Primary)
- Indications Hepatitis C; HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 27 Feb 2019 New trial record
- 19 Feb 2019 Results assessing drug-drug interactions (DDIs) between doravirine and two HCV treatments in two phase 1 drug interaction trials (MK-1439-053, MK-1439-050) published in the Antimicrobial Agents and Chemotherapy.